Episodes

In this podcast, we interviewed Ricardo Baptista, Lead Process Development Scientist, Cell and Gene Therapy Catapult, UK, about his impressions on current bioprocessing technologies for stem cell therapy manufacturing and possible future innovations. View show notes at cellculturedish.com/bioprocessing-technologies-stem-cell-therapy-manufacturing/

In this podcast, we interviewed Dr. Robert Preti about the past, present, and future of global cell therapy manufacturing. We also discussed major industry milestones, manufacturing challenges, and opportunities for the further improvements. View show notes at cellculturedish.com/cell-therapy-manufacturing-opportunities-challenges/ Robert A. Preti, PhDChief Executive Officer and President, Hitachi Chemical Advanced Therapeutics Solutions, LLCGeneral Manager, Regenerative Medicine Business Sect...

In this podcast, we interviewed Dr. Paul Wotton, CEO, about Sigilon Therapeutics’ discovery platform. The platform combines cell engineering and biocompatible Afibromer™ technology to enable cell therapies that do not trigger fibrosis View show notes at cellculturedish.com/novel-technology-enables-encapsulated-cell-therapeutics-without-triggering-fibrosis/

In this podcast, we interviewed Alyssa Master, Ph.D., Senior Manager of Science and Applications, Nucleus Biologics about some of the challenges of working with FBS, why not all FBS is created equal and suggestions for FBS customers who are trying to navigate these issues. We began the interview by discussing what FBS is and how it differs from other types of serum. Alyssa explained that FBS is a bi-product of the meat and dairy industry and it is great for in vitro cell growth because it conta...

In this podcast, we interviewed Dr. Adam Elhofy, Ph.D., Chief Scientific Officer, Bio-Ess, about the relationship between antibody titer and product quality attributes such as glycosylation. Dr. Elhofy shares his thoughts on both challenges and opportunities for optimizing both high titer and glycosylation profiles. View show notes at cellculturedish.com/sacrifice-antibody-titer-quality-employing-cell-biology-get-best-worlds/

In this podcast, we interviewed Ken Clapp, a senior member of GE Healthcare Life Sciences' upstream product management team. We explored in more detail the implementation of single-use systems for microbial fermentation including which processes make good candidates for single-use and considerations for transitioning from stainless steel. View show notes at cellculturedish.com/implementation-single-use-bioreactors-microbial-fermentation-easier-think/

In this podcast, we interviewed Ken Clapp, a senior member of GE Healthcare Life Sciences' upstream product management team. We discussed the use of single-use bioreactors for fermentation, how single-use technology has evolved to meet the more rigorous demands of fermentation, and the benefits of single-use for this application. View show notes at cellculturedish.com/single-use-bioreactors-fermentation-now-reality-deserves-consideration/

In this podcast, we interviewed Jim McGorry, CEO and Saverio LaFrancesca, President and Chief Medical Officer about how Biostage is using cell therapy to improve the standard of care in adult and pediatric esophageal disease. We began the interview talking with Dr. LaFrancesca about how Biostage is using their Cellframe technology to improve on the current standard of care for esophageal diseases. Dr. LaFrancesca began by explaining that esophageal disease patients are divided into two patient ...

In this podcast, we interviewed Sarah Simons, Automation Field Project Manager, Beckman Coulter Life Science, about how to improve lab productivity and reproducibility by "spring cleaning" your methods and taking a fresh look at existing workflows and protocols. Sarah works on custom solutions for liquid handling systems. She joined Beckman in 2008, as an Automation Field Applications Specialist, focused on automated protocol development and customer training & support. Sarah enjoys taking a fr...

In this podcast, we interviewed Philip Mathuis, Co-founder and CEO, Ovizio, about cell culture monitoring, the latest technology for monitoring cells in culture without the need for sampling and where monitoring could move in the future. Prior to co-founding Ovizio with Serge Jooris in 2010, Mr. Mathuis obtained an engineering degree in electronics and telecommunications. He started his career in the high-tech sector where he held management positions for large companies in several European cou...

In this podcast, we were fortunate to have a group of experts for a panel discussion on vaccine manufacturing and viral vector production. Interviewees: Hanna P. Lesch, PhD, Research and Development Director at Finvector Vision Therapies Jose Castillo, PhD, Co-Founder and CTO of Univercells Mario Philips, Vice President and General Manager, Single-Use Technologies, Pall Life Sciences Fabien Moncaubeig, Head of Cell Culture Technologies, Pall Life Sciences Show Notes are available at cellcul...

In this podcast, we interviewed Dr. Adam Elhofy, Ph.D., CSO, Essential Pharmaceuticals, about cell culture media optimization. We discussed the evolution of cell culture media optimization, current goals, and the latest strategies and tools being used.

Dr. Jan Bruder answers questions about the Max Planck Institutes use of automation in high throughput drug-screening for ALS and Parkinson’s Disease. for more info and to view the show notes go to cellculturedish.com/002-automated-stem-cell-based-high-throughput-drug-screening-for-als-and-parkinsons-disease/